On the bright side: Car wash dates, virtual walking tours in SF and the death of limousines – San Francisco Chronicle

Most car washes are just soap and water. Not the one in San Bruno.

Were trying to make it Disneyland caliber, said Bobak Bakhtiari, proprietor of the Tanforan Shell car wash. Were not quite there yet.

For $10, you drive into the car wash. The tunnel doors roll shut. Then the colored lights and space age music come on, along with the suds. Bahktiari calls it a virtual reality car wash. Its not Disneyland, but its pretty exciting for San Bruno.

A car wash could be the least dangerous thing you can do during a pandemic, Bahktiari said. No mask or sanitizer required. No staying six feet away from anything. Just you, inside your car, in the dark.

The car need not be dirty. In fact, Bakhtiari said, a lot of people have been driving through with clean cars, especially on date night, when a few minutes of privacy in the dark is worth $10, maybe more.

Car washes, Bahktiari said, speak to the human experience. Nobody doesnt like going through a car wash.

Bakhtiari inherited the car wash from his father 10 years ago and keeps pushing the envelope. Hes had lights and music for some time, but starting this month he upped the virtual reality trappings by hiring online artists to create each car wash sound-and-light show in real time. No two car washes are the same.

Its something like the colored light display at the top of the Salesforce Tower, or a planetarium visit minus the planets. Its also like a drive-in movie, with just as much smooching among the paying customers.

Even though he owns the place, Bakhtiari never cuts in the car wash line. The other evening he waited half an hour, like everyone else.

When his turn came, the blue Camry rolled into the tunnel. Seven projectors and nine loudspeakers came on. Swirls of colored lights filled the tunnel and swirls of soapsuds covered the windshield. Images of tropical fish swam by on the walls. Something that looked like a volcano erupted. There was a rainbow and a jellyfish. Music thumped and twanged. The suds blocked much of the show but they did get the car clean.

When it was over, the car inched down the exit lane past a giant dinosaur sculpture that had a likeness of Donald Trump in its jaws. Thats new, too. Watching the president get eaten is included in the $10.

Weve got something for everybody, the car wash man said. We trying to enhance the awe and wonder in the car wash experience. People need something fun to do right now thats also safe. This is it.

Walk this way: San Francisco will still be here long after the pandemic passes, and if you need proof, says a longtime Bay Area artist, just look up at the sides of the old buildings around town.

Hundreds of painted signs still remain, high up the brick walls. Eat Carnation mush, says one. Smoke Owl cigars or Zubelda cigarettes, say others.

Artist Kasey Smith calls them ghost signs. The products are mostly gone, along with the people who painted the signs and bought the products. But about 300 faded signs still remain. They hearken to the turn of the century not the last one but the one before.

You cant smoke an Owl cigar any more, and probably shouldnt anyway, but maybe your great grandpa did. Its all right there on the brick wall at 921 Post St.

The past is everywhere, said Smith. Eat at Ahrens Bakery. Drink Acme beer. Drink Rainier beer, too.

Smith, who has mapped the signs and posted them on her website (www.sfghostsigns.com) leads popular downtown walking tours, pointing out the signs and telling their stories. Since the pandemic, the tours have gone online instead of on foot.

The other night, about 150 people signed up for the free online tour of Tenderloin ghost signs. Walking through the star-crossed Tenderloin, one of her favorite parts of town, can be less heartbreaking by computer, Smith said.

The Carnation mush sign just southwest of the Tenderloin, high on a wall at 1586 Market St., could be her favorite. It was hidden for decades until the demolition of a nearby building in 2012 revealed it. The sign says Carnation mush comes in three kinds, but it doesnt say what they are.

Smith said shes pretty sure one kind was polenta, the snazzy name that cornmeal mush goes by in 2020.

A lot of the signs, Smith said, were painted shortly after the 1906 earthquake, another calamity that San Francisco lived through and got past. Together, the signs offer as much of a hope for the future as a glimpse of the past.

San Francisco has been through great tragedies before, and always comes out on top, she said. These signs speak to how resistant we are. Look up at them. Theyll tell you that the city can survive this.

A chance to rebrand: When people start going to the airport again, said the head of all limousines in the U.S., they arent going to be going in limousines.

Thats because, by then, he hopes to be calling them something else.

The word limousine is a problem for us, said Robert Alexander, president of the organization known (for the time being) as the National Limousine Association. Not as much of a problem as the virus, but its still a problem.

The association will get a new name if he has anything to say about it, which being the president he does. Maybe the term will be car service, as they call it back East, or livery, or private driver transportation.

The stigma of a long, black limousine that takes grieving widows to funerals and giddy high schoolers to proms is something that hurts all drivers of limousines, or whatever they are.

For the 2,000 members of the association, another big problem is persuading potential customers during a pandemic or any other time to pay two or three times as much to book a limousine, which these days is usually an SUV, instead of an Uber or taxi. Catching a Lyft from central San Francisco to the airport costs about $26, while a taxi costs about $39 and a limousine costs about $85.

Alexander said new rules for limousines call for free masks for all passengers, a thorough disinfecting of the vehicle after each ride and gloves for all drivers. Also sanitizer, lots of sanitizer.

But all the sanitizer in the world wont get people moving again before theyre ready, Alexander conceded. Right now, about nine out of 10 airplanes arent going anyplace. And about nine out of 10 limousines, or whatever they are, are arent going anyplace, either.

But well be ready when this thing is over, the limousine man said.

Steve Rubenstein is a San Francisco Chronicle staff writer. Email: srubenstein@sfchronicle.com Twitter: @SteveRubeSF

More here:

On the bright side: Car wash dates, virtual walking tours in SF and the death of limousines - San Francisco Chronicle

Now Available Virtual Reality In Education Sector Market Forecast And Growth 2036 – Bulletin Line

Global Virtual Reality In Education Sector market Research presents a Comprehensive scenario Which can be segmented according to producers, product type, software, and areas. This segmentation will offer deep-dive evaluation of this Virtual Reality In Education Sector business for identifying the development opportunities, development tendencies and factors limiting the development of the marketplace. This report features forecast market information based on previous and current Virtual Reality In Education Sector industry scenarios and growth facets. The Virtual Reality In Education Sector market share and market prognosis of every area from 2020-2027 are introduced within this report. A profound study of Virtual Reality In Education Sector marketplace dynamics can assist the marketplace aspirants in identifying the business opportunities that will cause accumulation of earnings. This section can efficiently determine the Virtual Reality In Education Sector market and crucial market driving forces.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2735256&source=atm

Precise view of this Global Virtual Reality In Education Sector market numbers and market quotes. Virtual Reality In Education Sector report Information represented in the kind of graphs, charts, and statistics will demonstrate the Virtual Reality In Education Sector growth speed, quantity, goal customer analysis. This report introduces the significant data to each of Virtual Reality In Education Sector business aspirants that will facilitate business decisions that are useful.

segment by Type, the product can be split intoVR HardwareVR SoftwareMarket segment by Application, split intoK-12 SectorHigher Education Sector

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2735256&source=atm

The Virtual Reality In Education Sector report pay after data points:

Part 1: This section enlists the Global Virtual Reality In Education Sector marketplace Summary, covering the simple market debut, market evaluation by kind, software, and areas. Virtual Reality In Education Sector business states and prognosis (2020-2027) is introduced in this part. Additionally, key word market dynamics saying the chances, market risk, and crucial driving forces are researched.

Part 2: This component covers Virtual Reality In Education Sector manufacturers profile based On their small business summary, product type, and program. Additionally, the sales quantity, Virtual Reality In Education Sector product cost, gross margin analysis, and Virtual Reality In Education Sector market share of every participant is profiled in this report.

Part 3 and Part 4: This component presents the Virtual Reality In Education Sector contest Based on earnings, earnings, and market share of every producer. Part 4 covers the Virtual Reality In Education Sector market situation based on areas. Region-wise Virtual Reality In Education Sector earnings and expansion (2015-2019) is analyzed in this report.

America and also Europes Virtual Reality In Education Sector business by states. Under this Virtual Reality In Education Sector earnings, market share of those nations like USA, Canada, and Mexico is supplied. Beneath Europe Virtual Reality In Education Sector report contains, the states such as Germany, UK, France, Russia, Italy, Russia and their earnings and growth is coated.

The earnings and expansion in these areas are introduced within this Virtual Reality In Education Sector business report.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2735256&licType=S&source=atm

Part 10 and Part 11: This component depicts the Virtual Reality In Education Sector marketplace Share, earnings, sales by product type and program. The Virtual Reality In Education Sector sales increase seen during 2012-2020 is covered within this report.

Associated with Virtual Reality In Education Sector economy (2020-2027) for every area. The sales channels such as indirect and direct Virtual Reality In Education Sector advertising, traders, vendors, and future trends are presented within this report.

Part 14 and Part 15: All these components present Virtual Reality In Education Sector market crucial Research findings and judgment, study methodology, and information sources are coated.

Therefore, Global Virtual Reality In Education Sector report is a whole blend covering all The very important market aspects.

Excerpt from:

Now Available Virtual Reality In Education Sector Market Forecast And Growth 2036 - Bulletin Line

Virtual Reality (VR) Market By Top Players, Latest Trends, Demand Analysis and Forecast to 2026 – 3rd Watch News

2020 july, Magarpatta SEZ, Pune,The newVirtual Reality (VR) Marketreport offers a comprehensive study of the present scenario of the market coupled with major market dynamic. Also, it highlights the in-depth market analysis with the latest trends, drivers and its segments with respect to regional and country. Further, this report profiles top key players of the Virtual Reality (VR) Market and analyze their market share, strategic development and other development across the globe

GetFree Sample PDF Copy of Virtual Reality (VR) Market with Figures, Graphs and Tocs:http://www.market-research-reports.com/contacts/requestsample.php?name=1073967

Market OverviewThe global Virtual Reality (VR) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 18.2% in the forecast period of 2020 to 2025 and will expected to reach USD 13310 million by 2025, from USD 6828.1 million in 2019.

The Virtual Reality (VR) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentationVirtual Reality (VR) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Virtual Reality (VR) market has been segmented into: Mobile Virtual Reality PC-side Virtual Reality Integrated Computer Virtual Reality

By Application, Virtual Reality (VR) has been segmented into: Commercial Household

Regions and Countries Level AnalysisRegional analysis is another highly comprehensive part of the research and analysis study of the global Virtual Reality (VR) market presented in the report. This section sheds light on the sales growth of different regional and country-level Virtual Reality (VR) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Virtual Reality (VR) market.

The report offers in-depth assessment of the growth and other aspects of the Virtual Reality (VR) market in important countries (regions), including: North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia) South America (Brazil, Argentina, Colombia) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Virtual Reality (VR) Market Share AnalysisVirtual Reality (VR) competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Virtual Reality (VR) sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Virtual Reality (VR) sales, revenue and market share for each player covered in this report.

The major players covered in Virtual Reality (VR) are: Netflix KNOXLABS Koncept VR Samsung Electronics I AM CARDBOARD Google PowisVR DODOcase Jaunt OnePlus Samsonite IP Holdings Unofficial Cardboard HTC Mattel ZEISS VR ONE Facebook (Oculus VR) HOMIDO

Market-Research-Reportsalso provides in depth study ofVirtual Reality (VR) Marketusing SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organisation. The Virtual Reality (VR) Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organisation such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organisation.

Enquire for More Information Virtual Reality (VR) Market:http://www.market-research-reports.com/contacts/inquiry.php?name=1073967

The global Virtual Reality (VR) Market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period. The research study on the global Virtual Reality (VR) Market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

This report studies the Virtual Reality (VR) Marketstatus and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Virtual Reality (VR) Marketby product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question. The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

The report helps to identify the main Virtual Reality (VR) Marketplayers. It assists in analyzing Virtual Reality (VR) Market competitive environment, including company overview, company total revenue, market opportunities, value, production sites and facilities, SWOT analysis, product details. The study also reveals the sales, revenue and market share for each market player included in this report for the period of 2015-2020. It also helps to ascertain the growth drivers and future prospects for the forecast timeline.

Conclusively, this report is a one stop reference point for the industrial stakeholders to get Virtual Reality (VR) Marketforecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

About Us: Market Research Reports is an aggregator of syndicated market research studies that offer current and future market intelligence across multiple industrial verticals through is high quality database. Additionally, with help of our sales and research experts focus, Market Research Reports aims to help you take business decisions accurately and on time, every time. Understanding your time constraints, we can help you find the most relevant research based on the requirements you share with us. Our customers get 24 X 7 email and phone support.

Contact us for your special interest needs and we will get in touch within 24hrs to help you find th e market research report you need.

E-mail: [emailprotected]

Phone: +1 888 391 5441

Follow this link:

Virtual Reality (VR) Market By Top Players, Latest Trends, Demand Analysis and Forecast to 2026 - 3rd Watch News

For 1st time in 75 years, world leaders wont travel to NY for UNGA as session goes virtual – The Tribune India

United Nations, July 23

World leaders will submit pre-recorded video statements for the United Nations General Assembly session in September, the 193-member organisation has decided, as heads of state and government will not be physically attending the annual gathering due to the coronavirus pandemic and the high-level session goes virtual for the first time in the UNs 75-year history.

The landmark 75th session of the UN General Assembly will begin on September 15. The General Debate is held at the beginning of each session of the General Assembly and usually runs for over a week when leaders and ministers from the 193 UN member states address the world from the iconic lectern in the General Assembly hall.

The General Assembly adopted a decision on Wednesday that each Member State, observer State and the European Union can submit a pre-recorded statement of its Head of State, Vice-President, Crown Prince or Princess, Head of Government, Minister or Vice-Minister, which will be played in the General Assembly Hall during the general debate of the Assembly at its seventy-fifth session, the high-level meeting to commemorate the seventy-fifth anniversary of the United Nations and the high-level meetings...after introduction by their representative who is physically present in the Assembly Hall.

While taking the decision, the General Assembly noted with concern the situation regarding the coronavirus pandemic and the limitations recommended on meetings within the United Nations premises as precautionary measures aimed at containing the spread of COVID-19.

The new format will mean that it will be for the first time in the world organisations 75-year history that global leaders will not gather here for the high-level week that annually brings thousands of diplomats, government officials, civil society members and media persons from around the world to New York City.

Telecommuting arrangements have been in place at the UN headquarters here since mid-March as coronavirus spread rapidly across New York, making the state the epicentre of the pandemic in the US.

The UN headquarters began its first phase of re-opening on July 20, under which no more than 400 people will be allowed to be present at the premises on any given day, in order to minimise the risk of exposure to the virus and to allow for physical distancing. Those present in the premises will have to follow strict social distancing guidelines.

The UN has said that given the evolving nature of the situation and the many remaining uncertainties regarding COVID-19, the transition from one phase to another may not be linear and at any time could revert to a previous phase.

In phase 2, the UNHQ occupancy will gradually increase from 10 to 40 per cent, while phase 3 or the new normal is being designed and will draw on lessons learned from the earlier phases.

The General Assembly meeting to commemorate the 75th anniversary of the United Nations will take place on September 21 and the Declaration will be formally adopted at the meeting. The General Debate of the 75th session of the Assembly will commence from September 22.

Along with the General Debate and 75th anniversary commemoration, key sessions will also be held virtually at the UN, the Assembly decided.

The summit on bio-diversity will be held on September 30, meeting of the General Assembly on the 25th anniversary of the Fourth World Conference on Women on October 1 and the meeting to commemorate and promote the International Day for the Total Elimination of Nuclear Weapons on October 2.

Member states will submit their pre-recorded video statements for these meetings as well. Each country would be encouraged to observe the time limit of 15 minutes in the General Debate that would include remarks in the Assembly Hall to introduce the pre-recorded video and the video itself.

General Assembly President Tijjani Muhammad-Bande told member states that with a view to limit the footprint and the number of people into the UN building, physical access and presence will be limited to one or, if the situation allows, two delegates in the General Assembly hall.

Further, he said member states are encouraged to move all side events to virtual platforms to limit the footprint and number of people in the UN building.

Addressing a virtual press conference in June, Muhammad-Bande had said that world leaders cannot come to New York for the annual UN General Assembly session in September because of the COVID-19 pandemic.

World leaders cannot come to New York because they cannot come as single individuals. A president doesnt travel alone. We dont expect therefore to have presidents here, Muhammad-Bande had said.

The General Assembly session had particular significance this year as it would have commemorated 75 years of the existence of the United Nations and would have seen tremendous participation from leaders of the 193 member states to mark the anniversary. PTI

See the rest here:

For 1st time in 75 years, world leaders wont travel to NY for UNGA as session goes virtual - The Tribune India

These Disney World attractions didn’t reopen when the park did. Here’s what we know – USA TODAY

As Walt Disney World reopens, here are some new health and safety measures you may see. USA TODAY

Walt Disney World may have reopened to the public this month, but that doesn't mean every attraction at the Florida theme park came back from a nearly four-month shutdown due to the coronavirus pandemic.

To be sure, not all of the ongoing closures are related to the coronavirus. Some attractions were simply scheduled to close permanently, while others are shut down for refurbishment. New attractions that were scheduled to open have been delayed.

Disney World reopened on July 11 with a variety of changes aimed at protecting visitors and stemming the spread of coronavirus. Visitors and employees must undergo a temperature screening on arrival. Both are required to wear face masks, except when eating or drinking. Social distancing is enforced throughout the park, and hand hygiene is encouraged.

Some events, like parades and fireworks, have not returned to avoid creating crowds.

No eating and walking: Universal Orlando, Disney World tightening face mask requirements, closing loopholes

Disney's theme parks lost $1 billion in income during the first three months of the year, the company reported in May.

"Like so many other companies andindustries, the pandemic has hit us hard," Disney ExecutiveChairman Bob Iger said as the company issuedits quarterlyfinancial results.

Walt Disney, who grew up in the railroad town of Marceline, Missouri, was a train guy. The Walt Disney World Railroad encircles the park with four restored narrow-gauge steam trains built from 1916 to 1928. The railroad is currently closed for refurbishment.

Three Disney World attractions will not be coming back, according to the company.Primeval Whirl and Rivers of Light were part of the Animal Kingdom. Stitch's Great Escape will not return at the Magic Kingdom. The closures were not related to the pandemic.

The Mary Poppins attraction at Epcot's British Pavilion is postponed, while an overhaul of Spaceship Earth, one of Disney World's most recognizable landmarks, will be delayed. The project was scheduled to begin in May. It will be the fourth update to Spaceship Earth since Epcot opened in 1982.

Disney World's water parks,Blizzard Beach and Typhoon Lagoon, have not reopened, with no date set for them to resume, according to the company.

No park hopping for now: Disney to roll out new reservation system when parks reopen

Disneyland was scheduled to reopen on July 17, but a surge in coronavirus cases in California has put that on hold. A new reopening date has not yet been announced.

Depending on when the park reopens, four attractions may remain closed for refurbishment: Gadget's Go Coaster, Snow White's Scary Adventures, King Arthur Carousel and Haunted Mansion. In the Disney California Adventure Park, the Red Car Trolley is also closed for refurbishment.

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/travel/experience/america/theme-parks/2020/07/23/disney-world-attractions-didnt-all-reopen-when-florida-park-did/5493584002/

See original here:

These Disney World attractions didn't reopen when the park did. Here's what we know - USA TODAY

AP FACT CHECK: Trump’s alternate reality on COVID-19 threat – KWTX

WASHINGTON (AP) - President Donald Trump appears to be living in an alternate reality when it comes to the COVID-19 threat.

Over the weekend, he clung to the misguided notion that the virus will just "disappear" even as his top science experts and GOP allies bluntly say otherwise.

Trump also continued to wrongly insist that anyone who wants a coronavirus test is getting one, made the head-scratching suggestion that the virus is under control when infections are surging to fresh daily highs and lodged false accusations against the nation's top infectious diseases expert, Dr. Anthony Fauci.

The statements came in a week of distorted truth. Trump referred repeatedly to his "ban" on travel from China that wasn't so and issued a scattered indictment of Democratic presidential rival Joe Biden.

A look at his rhetoric and how they compare with the facts:

TRUMP vs. FAUCI

TRUMP: "Dr. Fauci at the beginning said, 'This will pass. Don't worry about it. This will pass.' He was wrong." - interview aired on "Fox News Sunday."

THE FACTS: Trump is overstating it. While Fauci said in January and February that Americans need not panic about a virus threat at the time, he also said the situation was "evolving" and that public health officials were taking the threat seriously.

"Right now the risk is still low, but this could change, I've said that many times," Fauci told NBC on Feb. 29. He allowed that if there are growing cases of community spread, it could become a "major outbreak."

"When you start to see community spread, this could change and force you to become much more attentive to doing things that would protect you from spread," Fauci said.

Fauci never claimed the virus would just "pass" or disappear.

___

TRUMP: "Dr. Fauci told me not to ban China, it would be a big mistake. I did it over and above his recommendation." - Fox interview.

THE FACTS: That's incorrect. While Fauci expressed some initial reservations about travel restrictions on China, he supported the decision by the time it was made.

Health and Human Services Secretary Alex Azar, who was coordinator of the White House coronavirus task force at the time and announced the travel restrictions, said Trump made the decision in late January after accepting the "uniform recommendation of the career public health officials here at HHS."

While the World Health Organization did advise against the overuse of travel restrictions, Azar told reporters in February that his department's career health officials had made a "considered recommendation, which I and the president adopted" in a bid to slow spread of the virus.

___

TRUMP: "I will be right eventually. You know I said, 'It's going to disappear.' I'll say it again. It's going to disappear, and I'll be right." - Fox interview.

TRUMP: "We'll put out the flames. ... It's going to be under control." - Fox interview.

THE FACTS: "The virus is not going to disappear," according to Fauci.

The number of confirmed cases in the U.S. per day has risen over the past month, hitting over 70,000 this past week, according to a count kept by Johns Hopkins University. That is higher even than what the country experienced from mid-April through early May, when deaths sharply rose.

Fauci has warned that the increase across the South and West "puts the entire country at risk" and that new infections could reach 100,000 a day if people don't start listening to guidance from public health authorities to wear a mask and practice social distancing.

Arizona, California, Florida and Texas have recently been forced to shut down bars and businesses as virus cases surge. The U.S. currently has more than 3.7 million known cases and many more undetected.

In February, Trump asserted coronavirus cases were going "very substantially down, not up," and told Fox Business it will be fine because "in April, supposedly, it dies with the hotter weather."

Senate Majority Leader Mitch McConnell, visiting a hospital Wednesday in Kentucky, acknowledged that some of those early predictions were too rosy. "The straight talk here that everyone needs to understand: This is not going away," he said.

Fauci says there "certainly" will be coronavirus infections in the fall and winter.

___

PETER NAVARRO, White House trade adviser: "When Fauci was telling the White House Coronavirus Task Force that there was only anecdotal evidence in support of hydroxychloroquine to fight the virus, I confronted him with scientific studies providing evidence of safety and efficacy. A recent Detroit hospital study showed a 50% reduction in the mortality rate when the medicine is used in early treatment." - op-ed published Wednesday in USA Today.

THE FACTS: Navarro cherry-picks a study widely criticized as flawed and ignores multiple studies finding hydroxychloroquine doesn't help.

Numerous rigorous tests of hydroxychloroquine, including a large one from Britain and one led by the National Institutes of Health, concluded that the anti-malaria drug was ineffective for treating hospitalized coronavirus patients. Fauci leads the National Institute of Allergy and Infectious Diseases at NIH.

The Food and Drug Administration also has warned the drug should only be used for the coronavirus in hospitals and research settings because of the risk of serious heart rhythm problems and other safety issues.

The Henry Ford Health System study that Navarro refers to was an observational look back at how various patients fared. It was not a rigorous test where similar patients are randomly assigned to get the drug or not and where each group is compared later on how they did.

In the study, some people with heart or certain other conditions were not given the drugs, which can cause heart rhythm problems, so those patients were fundamentally different from the group they were compared with. Researchers said they adjusted statistically for some differences, but the many variables make it tough to reach firm conclusions.

Some patients also received other treatments such as steroids and the antiviral drug remdesivir, further clouding any ability to tell whether hydroxychloroquine helped.

The White House said Navarro was not authorized to challenge Fauci with the op-ed and should not have done it. But his points largely reflect ones Trump and others in the White House have made themselves.

___

MORE ON VIRUS THREAT

TRUMP, on what happened after he restricted travel from China: "Nancy Pelosi was dancing on the streets of Chinatown in San Francisco a month later, and even later than that, and others, too." - Rose Garden remarks Tuesday.

THE FACTS: No she wasn't. This is Trump's frequent and fanciful account of the House speaker's visit to San Francisco's Chinatown on Feb. 24. That day, she visited shops and strolled the streets to counter the hostility some people in the district were encountering over a virus that emanated from China.

On that day, Pelosi said the public should be vigilant about the virus but the city took precautions and "we should come to Chinatown." Local TV news tracked her visit;. She wasn't seen dancing and did not call for a "street fair," as Trump at times has put it. Community spread of the coronavirus had not yet been reported.

As FactCheck.org pointed out, the same day Pelosi went to Chinatown, Trump tweeted: The Coronavirus is very much under control in the USA. We are in contact with everyone and all relevant countries. CDC & World Health (Organization) have been working hard and very smart. Stock Market starting to look very good to me! The CDC is the Centers for Disease Control and Prevention.

Two days later, Trump asserted that only 15 people in the U.S. were infected and that number would go down "close to zero." Instead the numbers exploded. More than 3.6 million Americans have had COVID-19.

Trump has accused Pelosi of being "responsible for many deaths" because of the Chinatown visit. He has denied responsibility for any of the deaths sweeping the country as he has persistently minimized the threat, pushed for reopening and refused to take mask-wearing seriously.

___

TESTING

TRUMP: "We go out into parking lots and everything, everybody gets a test." - Fox interview.

THE FACTS: He's repeating the false notion that anybody who wants a COVID-19 test can get one.

Americans are being confronted with long lines at testing sites. People often are disqualified if they are not showing symptoms and, if they are tested, they sometimes are forced to wait many days for results.

Julie Khani, president of the American Clinical Laboratory Association, which represents LabCorp, Quest Diagnostics and other labs, has made clear that "the anticipated demand for COVID-19 testing over the coming weeks will likely exceed members' testing capacities." This past week the group encouraged members to give priority to "those most in need, especially hospitalized and symptomatic patients."

Many governors and local officials say they cannot meet the demand.

"Testing has been a challenge everywhere," says Utah Republican Gov. Gary Herbert.

Around Seattle, for instance, a new wave of patients is showing up at emergency departments, said nurse Mike Hastings.

"What's really frustrating from my side of it is when a patient comes into the emergency department, and is not really having symptoms of COVID, but they feel like they need that testing," said Hastings, who is president of the Emergency Nurses Association. "Sometimes we're not able to test them because we don't have enough test supplies, so we're only testing a certain set of patients."

___

TRUMP: "Cases are up, because we have the best testing in the world and we have the most testing." - Fox interview.

THE FACTS: It's not true that infections are high only because the U.S. diagnostic testing has increased. Trump's own top public health officials have shot down this line of thinking. Infections are rising because people are infecting each other more than they were when most everyone was hunkered down.

Increased testing does contribute to the higher numbers, but there's more to it. Testing in fact has uncovered a worrisome trend: The percentage of tests coming back positive for the virus is on the rise across nearly the entire country.

That's a clear demonstration that sickness is spreading and that the U.S. testing system is falling short.

"A high rate of positive tests indicates a government is only testing the sickest patients who seek out medical attention and is not casting a wide enough net," says the Johns Hopkins University Coronavirus Resource Center, a primary source of updated information on the pandemic.

___

TRUMP: "No country has ever done what we've done in terms of testing. We are the envy of the world. They call and they say the most incredible job anybody's done is our job on testing, because we're going to very shortly be up to 50 million tests. You look at other countries; they don't even do tests. ... They don't go around have massive areas of testing, and we do." - Fox interview.

THE FACTS: U.S. testing is not the envy of the world, nor is the U.S. the only country that does mass testing.

U.S. testing on a per capita basis lags other countries that have done a far better job of controlling their outbreaks. State, local and federal officials are warning of the consequences of testing bottlenecks, including tests rendered useless because results come too late.

China has used batch testing, mixing samples and testing them together, as part of a recent campaign to test all 11 million residents of Wuhan. It's an approach that top U.S. health officials believe could be used to boost U.S. screening, though it's not clear when pooled testing could become available for wide-scale screenings at U.S. schools and businesses.

"We are nowhere near being able to rein in this virus with the amount of testing we have available at the moment," said Dr. Leana Wen, an emergency physician and public health professor at George Washington University who previously served as Baltimore's health commissioner.

Dr. Francis Collins, director of the National Institutes of Health, said test results in parts of the U.S. take as long as a week, which is "too long."

"You do the testing to find out who's carrying the virus and then quickly get them isolated so they don't spread it around," he said Sunday on NBC's "Meet the Press." "And it's very hard to make that work when there's a long delay built in."

___

DEATH RATES

TRUMP: "I think we have one of the lowest mortality rates in the world." - Fox interview.

CHRIS WALLACE, host of "Fox News Sunday": "That's not true, sir."

TRUMP: "Number one, low mortality rate." - Fox interview.

THE FACTS: Trump's claim is wholly unsupported.

An accurate death rate is impossible to know. Every country tests and counts people differently, and some are unreliable in reporting cases. Without knowing the true number of people who become infected, it cannot be determined what portion of them die.

Using a count kept by Johns Hopkins University, you can compare the number of recorded deaths with the number of reported cases. That count shows the U.S. experiencing more deaths as a percentage of cases than most other countries now being hit hard with the pandemic. The statistics look better for the U.S. when the list is expanded to include European countries that were slammed early on by the virus but now appear to have it under control. Even then, the U.S. is not shown to be among the best in avoiding death.

Such calculations, though, do not provide a reliable measurement of actual death rates because of the variations in testing and reporting, and the Johns Hopkins tally is not meant to be such a measure.

The only way to tell how many cases have gone uncounted, and therefore what percentage of infected people have died from the disease, is to do another kind of test comprehensively, of people's blood, to find how many people bear immune system antibodies to the virus. Globally, that is only being done in select places.

___

TRAVEL RESTRICTIONS

TRUMP: "If you remember, I was the one that did the European Union very early." - Fox interview.

THE FACTS: U.S. health officials actually believe Trump was late in restricting travel from parts of Europe.

While Trump imposed travel restrictions on China in late January, he didn't follow up with many European countries until mid-March. Those delayed travel alerts as well as limited testing contributed to the jump in U.S. cases starting in late February, according to Dr. Anne Schuchat, the No. 2 official at the U.S. Centers for Disease Control and Prevention.

"We clearly didn't recognize the full importations that were happening," Schuchat told The Associated Press in May.

___

TRUMP: "We would've had thousands of people additionally die if we let people come in from heavily infected China. But we stopped it. We did a travel ban in January. ... By closing up, we saved millions, potentially millions of lives." - Rose Garden remarks

THE FACTS: He didn't ban travel from China. He restricted it. Dozens of countries took similar steps to control travel from hot spots before or around the same time the U.S. did.

The U.S. restrictions that took effect Feb. 2 continued to allow travel to the U.S. from China's Hong Kong and Macao territories over the past five months. The Associated Press reported that more than 8,000 Chinese and foreign nationals based in those territories entered the U.S. in the first three months after the travel restrictions were imposed.

Additionally, more than 27,000 Americans returned from mainland China in the first month after the restrictions took effect. U.S. officials lost track of more than 1,600 of them who were supposed to be monitored for virus exposure.

Few doubt that the heavy death toll from COVID-19 would be even heavier if world travel had not been constricted globally. But Trump has no scientific basis to claim that his action alone saved "millions" or even "hundreds of thousands" of lives, as he has put it.

___

TRUMP, on Biden: "He opposed my very strict travel ban on Chinese nationals to stop the spread of the China virus. He was totally against it. 'Xenophobic,' he called me. 'Xenophobic.' A month later, he admitted I was right." - Rose Garden.

THE FACTS: No, Biden did not come out against the travel restrictions on China. He said little about them at the time. In April, his campaign said he supported travel restrictions if "guided by medical experts."

Biden did say Trump has a record of xenophobia, a comment made during an Iowa campaign event when the restrictions were announced. Biden said Trump was "fear-mongering" against foreigners and the Democrat took issue with Trump's references to the "China virus" as an example. He did not address the travel steps.

Trump has claimed that Biden realized he was right after all about restricting travel from China and wrote him a "letter of apology." This didn't happen, either.

___

POLICE

TRUMP: "Biden wants to defund the police." - Fox interview.

THE FACTS: To be clear, Biden has not joined the call of protesters who demanded "defund the police" after George Floyd's killing in Minneapolis. He's proposed more money for police, conditioned to improvements in their practices.

"I don't support defunding the police," Biden said last month in a CBS interview. But he said he would support tying federal aid to police based on whether "they meet certain basic standards of decency, honorableness and, in fact, are able to demonstrate they can protect the community, everybody in the community."

Biden's criminal justice agenda, released long before he became the Democrats' presumptive presidential nominee, proposes more federal money for "training that is needed to avert tragic, unjustifiable deaths" and hiring more officers to ensure that departments are racially and ethnically reflective of the populations they serve.

Read the original post:

AP FACT CHECK: Trump's alternate reality on COVID-19 threat - KWTX

Global Travel Bag Market Report Explores Share, Development By Companies Outlook, Growth Prospects And 2026 Key Opportunities Forecast – Cole of Duty

Travel Bag Market is systematic exploration that delivers key statistics on the market status of the development trends, competitive landscape analysis, and key regions development status. The report has included strong players and analyses their limitations and strong points of the well-known players through SWOT analysis. This Report covers growing trends that are linked with major opportunities for the expansion of the Travel Bag industry.

Get Free Sample Report(including full TOC, Tables and Figures): @ https://www.globalmarketers.biz/report/life-sciences/global-travel-bag-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/155811#request_sample

Ace Co. Ltd.EverestSamsonite Company StoresVIP Industries Ltd.CrownUnited States Luggage Company (LLC)TumiTravelpro International Inc.RimovaAmerican TouristerEagle CreekAntlerShanghai Fochier Intel Co. Ltd.Targus Group International Inc.Delsey SA

The Geographical Analysis Covers the Following Regions

The recent outbreak of the COVID-19 (Corona Virus Disease) Provide extra commentary on the newest scenario, an economic slowdown on the overall industry. In addition to this, the report also includes the development of the Travel Bag market in the major regions across the world.

Note: Upto 30% Discount: Get this reports in Discounted Price

Ask For Discount: https://www.globalmarketers.biz/discount_inquiry/discount/155811

Global Travel Bag Market Segmentation: By Types

MenWomenKids

Global Travel Bag Market Segmentation: By Applications

Travel PacksLightweight Carry-OnsWheeled Duffel Bags and Rolling LuggageBackpacks and Wheeled Backpacks

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.globalmarketers.biz/report/life-sciences/global-travel-bag-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/155811#inquiry_before_buying

This research report represents a 360-degree overview of the competitive landscape of the Travel Bag Market. Furthermore, it offers enormous statistics relating to current trends, technological advancements, tools, and methodologies.

Global Travel Bag Market Research Report 2020

Chapter 1 About the Travel Bag Industry

Chapter 2 World Market Competition Landscape

Chapter 3 World Travel Bag Market share

Chapter 4 Supply Chain Analysis

Chapter 5 Company Profiles

Chapter 6 Globalization & Trade

Chapter 7 Distributors and Customers

Chapter 8 Import, Export, Consumption and Consumption Value by Major Countries

Chapter 9 World Travel Bag Market Forecast through 2027

Chapter 10 Key success factors and Market Overview

It concludes by throwing light on the recent developments that took place in the Travel Bag market and their influence on the future growth of this market.

Table of Content & Report Detail @ https://www.globalmarketers.biz/report/life-sciences/global-travel-bag-market-report-2020-by-key-players,-types,-applications,-countries,-market-size,-forecast-to-2026-(based-on-2020-covid-19-worldwide-spread)/155811#table_of_contents

Read more here:

Global Travel Bag Market Report Explores Share, Development By Companies Outlook, Growth Prospects And 2026 Key Opportunities Forecast - Cole of Duty

Virtual tourism in Africa takes off amid the coronavirus pandemic – DW (English)

The sun rises slowly above the horizon of the African savanna. Against its glowing light can be seen the silhouettes of an elephant family rambling through the grassland on their quest for the nearest waterhole. Impalas and zebras make their way through the wilderness, the birds chirp and it can be sensed that the day is going to be a hot one.

This scene in the Sabi Sand Game Reserve in Mpumalanga, one of the best-known safari regions of South Africa, seems very real. But, in fact, the tourists who are enjoying it are not sitting in jeeps, but at home watching it on their smartphones and tablets. The safari itself is really taking place, however, and, as in real life, every trip is different, adding to the pleasure of such virtual experiences.

In the Kenyan game reserve Ol Pejeta you can go on a virtual safari with rangers.

Since the coronavirus pandemic broke out, the tourism industry has collapsed across all the countries in Africa. National parks and hotels are empty and there is no trace of tourists, as they are all stuck at home.

But several African tourism associations have come up with the idea of supplying avid travelers with digital impressions of the continent during the pandemic. Virtual tourism is on the rise.

Safaris at home

Safaris in Kenya, strolls through the Namib desert in Namibia, paragliding in South Africa or standing on the edge of the Victoria Falls at the border between Zambia and Zimbabwe: All of these experiences can now be enjoyed at home by virtual tourists like Juan Santiago.

Santiago, who hails from the Spanish capital, Madrid, has already visited Kenya a couple of times at this time of year to watch the migration of wildebeest in the Maasai Mara game reserve, a phenomenon that has often been called one of the Wonders of the World.

But this year, things are different. Instead of going to Kenya, Santiago is paying a virtual visit to the Nairobi National Park. "If the safari is led well, you have the atmosphere of the Nairobi National Park at home. Everything happens in real time," he says. "Even if my family tours Kenya without me after the coronavirus pandemic, this technology lets me accompany them virtually."

Conventional safaris are important for earning foreign currencies, especially in eastern and southern Africa.

Read more:Protecting South African wildlife from poaching during the coronavirus pandemic

A chance to survive

Kenya has already lost more than $750 million (656 million) in revenue from tourism since the first case of COVID-19 in the country. That is why, in June, the tourism authority there initiated a live-stream drive as part of its #TheMagicAwaits campaign. It is meant to give the world a taste of what awaits in Kenya when the country is open to visitors once more, says Betty Radier, the managing director of the Kenya Tourism Board.

"People are online and looking for places they could travel to. That is a great opportunity for us to present ourselves live as a destination," she told DW. Sixteen different destinations in Kenya are being live-streamed.

A taste of things to come

This concept is also working in South Africa. The tourism authority in Cape Town, for example, has launched the campaign We Are Worth Waiting For. It is offering ways to enjoy the city virtually, including tours on Robben Island, with its former prison, and Table Mountain.

The managing director of Cape Town Tourism, Enver Duminy, describes it as a long-distance love affair.

"What we have done using technology during COVID-19 is to use social media and campaigns to remind tourists of why they fell in love with the destination in the first place," Duminy told DW. "We give images of what you are longing for, of what you experienced the last time you were here. And hopefully we can connect and continue that love affair when you visit us. Technology is more of an enabler that allows us to transit in space and time."

"Virtual tourism is a great opportunity for seeing whether you want to visit a particular destination for real," says Gerald Ferreira, the founder of the Virtual Reality Company in South Africa. "People can also try out what adventure tourism is like before they try something like bungee jumping, for example."

Read more:Faraway peaks and unreachable cities virtual travel is all that's possible for the time being

Rapid growth

According to figures from the UN's World Tourism Organization (UNWTO), 74% of African governments were not allowing tourists into their countries at the start of June. Before the pandemic broke out, Africa was the fastest-growing tourism region. In 2018, some 67 million tourists visited the continent, bringing $38 billion in revenue. In 2019, the number of tourists increased by 4.2%, according to preliminary figures. And Africa could have reckoned with an increase of 3-4% in 2020.

But then, COVID-19 arrived on the scene. The World Travel and Tourism Council (WTTC) puts the number of jobs lost in Africa's tourism sector alone at almost 8 million. This has made seeking alternatives imperative.

But can virtual tourism replace real travel? Or could it even cause long-term damage to the tourism industry, with potential travelers staying away, content with visiting Africa virtually?

Read more:How COVID-19 is destroying Africa's tourism industry

Itchy feet syndrome

Patrick Karangwa, a computer scientist from Rwanda, does not think it will. He offers virtual tours through the capital, Kigali.

"I don't see myself as competing with traditional tourism, but as a partner," he told DW. "I create an additional layer of information that encourages people to travel to places. It is really an advantage for travel businesses, hotels, restaurants and the industry in general."

Enver Duminy in Cape Town is also banking on people's continued wanderlust. "Virtual reality allows more immersive experiences, even though at this stage it does not allow you to touch and taste and smell. It only allows you to see. I think it is in our DNA; we need to connect, to see, to touch, to hug."

In a few weeks' time, the first package tourists from Europe are due in Rwanda again. Tanzania, known for its lax approach to the coronavirus crisis, is already welcoming tourists, and Namibia has reopened its national parks. Kenya will allow tourists in from August 1 and South Africa's tourism industry hopes to be able to open for business from September 2020 whether that will really be the case, however, remains uncertain, as cases of coronavirus infection are currently rising. Countries like Uganda will probably have to wait a bit longer.

Read more:Corona-hit tourism in Kenya leaves elephant conservation 'staring at an uncertain future'

Animal welfare benefits

Juan Santiago in Madrid is not worried by this. Since the pandemic started, he has already taken a virtual look at the famous archaeological finds and collections in the Nairobi National Museum.

Even if he likes to travel in these countries in person, he believes in the future of virtual tourism. "One day, we will all be able to see the giraffes in Nairobi from all over the world; you'll go to work at 8 o'clock and watch the giraffes on live screens in the office," he says. "That will be good for nature conservation because nature fans like me would then donate for these giraffes, rhinoceroses or elephants."

Anyone who already has itchy feet can only hope that trips to Africa will soon be possible again. But for those who are content with virtual travel as well the world is already open.

See the original post:

Virtual tourism in Africa takes off amid the coronavirus pandemic - DW (English)

A functional genomics approach to investigate the differentiation of iPSCs into lung epithelium at air-liquid interface. – Physician’s Weekly

The availability of robust protocols to differentiate induced pluripotent stem cells (iPSCs) into many human cell lineages has transformed research into the origins of human disease. The efficacy of differentiating iPSCs into specific cellular models is influenced by many factors including both intrinsic and extrinsic features. Among the most challenging models is the generation of human bronchial epithelium at air-liquid interface (HBE-ALI), which is the gold standard for many studies of respiratory diseases including cystic fibrosis. Here, we perform open chromatin mapping by ATAC-seq and transcriptomics by RNA-seq in parallel, to define the functional genomics of key stages of the iPSC to HBE-ALI differentiation. Within open chromatin peaks, the overrepresented motifs include the architectural protein CTCF at all stages, while motifs for the FOXA pioneer and GATA factor families are seen more often at early stages, and those regulating key airway epithelial functions, such as EHF, are limited to later stages. The RNA-seq data illustrate dynamic pathways during the iPSC to HBE-ALI differentiation, and also the marked functional divergence of different iPSC lines at the ALI stages of differentiation. Moreover, a comparison of iPSC-derived and lung donor-derived HBE-ALI cultures reveals substantial differences between these models. 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

PubMed

Read the original post:

A functional genomics approach to investigate the differentiation of iPSCs into lung epithelium at air-liquid interface. - Physician's Weekly

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic…

NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, and the University of Connecticut School of Medicine (UConn), today announced a research collaboration and license agreement to accelerate the development of a next-generation short hairpin RNA (shRNA)-based therapeutic for Angelman syndrome and potentially other indications. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. An shRNA-based therapeutic may address this underlying genetic cause of Angelman syndrome by reducing the expression of UBE3A-antisense, potentially restoring the function of UBE3A. This genetic approach may be used in combination with OV101 (gaboxadol), Ovids novel, small-molecule delta ()-selective GABAA receptor agonist, to restore tonic inhibition and address the underlying symptomology of individuals with Angelman syndrome. OV101 is currently being evaluated in the pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020.

Under the terms of the research collaboration, Ovid will work closely with UConns Stormy J. Chamberlain, Ph.D., and gain exclusive access to identified genetic sequences for a potential shRNA-based therapeutic. Ovid plans to validate select sequences and leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance an shRNA-based therapeutic into clinical studies. Dr. Chamberlain is a recognized leader in the field of Angelman syndrome and UBE3A research and currently serves as the John and Donna Krenicki Associate Professor of Genomics and Personalized Healthcare in UConns Genetics and Genome Sciences Department. In addition, Dr. Chamberlain chairs the Angelman Syndrome Foundation (ASF) Scientific Advisory Committee and is a member of the Dup15q Alliance Scientific Advisory Board. Ovid will also work closely with UConns Noelle Germain, Ph.D., Assistant Professor of Genetics and Genome Sciences on these efforts.

Ovid is deeply committed to the Angelman syndrome community. We have made great progress and are excited to see the topline data from our Phase 3 NEPTUNE trial with OV101 expected in Q4 2020, said Amit Rakhit, M.D., MBA, President and Chief Medical Officer of Ovid Therapeutics. We believe OV101 has the potential to serve as a core therapy for this disorder and are now focused on building a comprehensive and strategic Angelman syndrome longer term pipeline. If successful, OV101 may be used in combination with genetic approaches in the future to address the needs of Angelman syndrome. This collaboration with Drs. Chamberlain and Germain, both accomplished scientific leaders in the field of Angelman syndrome, will enable us to accelerate and share in their mission to identify and develop next-generation genetic therapies. Together with our early-stage microRNA approach, this research collaboration now provides us with additional targets against this disorder, greater strategic optionality, and underpins our broad capability to bring new therapies to individuals living with Angelman syndrome both near-term and into the future.

Our lab shares in Ovids demonstrated commitment to advance innovative therapeutic options for Angelman syndrome, stated Dr. Chamberlain. An shRNA therapeutic can target the genetic cause of Angelman syndrome at its source and may offer potential advantages to other next-generation approaches, including antisense oligonucleotide therapy, via a lower rate of degradation and turnover and plasmid delivery allowing for a less-frequent dosing profile. Ovid is uniquely positioned to accelerate an shRNA therapeutic through late preclinical and clinical development, and our lab looks forward to working with the team at Ovid towards our common objective of impacting the lives of individuals living with Angelman syndrome and their families.

About Angelman Syndrome Angelman syndrome is a rare genetic condition that is characterized by a variety of signs and symptoms. Characteristic features of this condition include delayed development, intellectual disability, severe speech impairment, problems with movement and balance, seizures, sleep disorders and anxiety. The most common cause of Angelman syndrome is the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), which plays a critical role in nerve cell communication, resulting in impaired tonic inhibition. Individuals with Angelman syndrome typically have normal lifespans but are unable to live independently. Therefore, they require constant support from a network of specialists and caregivers. Angelman syndrome affects approximately 1 in 12,000 to 1 in 20,000 people globally.

There are no approved therapies by the U.S. Food and Drug Administration (FDA), European Medicines Agency or rest-of-world for Angelman syndrome, and treatment primarily consists of behavioral interventions and pharmacologic management of symptoms.

Angelman syndrome is associated with a reduction in tonic inhibition, a function of the delta ()-selective GABAA receptor that allows a human brain to decipher excitatory and inhibitory neurological signals correctly without being overloaded. If tonic inhibition is reduced, the brain becomes inundated with signals and loses the ability to separate background noise from critical information.

Ovid is developing OV101 for the treatment of Angelman syndrome to potentially restore tonic inhibition and thereby address several core symptoms of Angelman syndrome. Ovid is conducting a pivotal Phase 3 clinical trial with OV101 in Angelman syndrome (NEPTUNE), with topline results expected in the fourth quarter of 2020. In addition, Ovid is also exploring OV881, a microRNA approach that may reduce the expression of UBE3A-antisense and potentially restore UBE3A expression.

About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Companys most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE). For more information on Ovid, please visit http://www.ovidrx.com.

About UConnUConn Health is Connecticuts only public academic medical center. Based on a 206-acre campus in Farmington, UConn Health has a three-part mission: research, teaching and patient care. Home to the UConn School of Medicine, School of Dental Medicine and UConn John Dempsey Hospital with over 5,000 employees supporting nearly 1,000 students, over 800,000 annual patient visits, and innovative scientific research contributing to the advancement of medicine. For more information, visit health.uconn.edu.

Ovid Forward-Looking StatementsThis press release includes certain disclosures that contain forward-looking statements, including, without limitation, statements regarding: development of short hairpin RNA based therapeutics, development of combination therapies, potential benefits of OV101, anticipated reporting schedule of clinical data for OV101 and the potential benefits and value of this collaboration. You can identify forward-looking statements because they contain words such as will, appears, believes and expects. Forward-looking statements are based on Ovids current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovids filings with the Securities and Exchange Commission under the caption Risk Factors. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovids business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Ovid Therapeutics Contacts

Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com

Or

Investors: Steve KlassBurns McClellan, Inc.sklass@burnsmc.com(212) 213-0006

Media:Katie Engleman1ABkatie@1abmedia.com

UConn ContactJessica McBride, PhDjessica.mcbride@uconn.edu860-878-5058

Read this article:

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic...

Global Bioinformatics Market To See Booming Worldwide | Top Key Players- Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc. – 3rd Watch News

A recent report published by QMI on bioinformatics market is a detailed assessment of the most important market dynamics. After carrying out thorough research on the market of bioinformatics historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for bioinformatics during the forecast period. It can enable manufacturers of bioinformatics to change their production and marketing strategies in order to envisage maximum growth. The market report on bioinformatics offers detailed information for stakeholders in the most comprehensive way on the current and future growth prospects of the demand for bioinformatics market.

To Request Sample Premium Reports:https://www.quincemarketinsights.com/request-sample-60484?utm_source=SSK&utm_medium=3WN&utm_campaign=SSK

This report provides comprehensive taxonomy and the description of industry-related products, applications and end-user channels for the bioinformatics market. This report also provides insight into market concepts for phase. This contains opportunity analysis which provides information on the most relevant macroeconomic and microeconomic factors affecting market revenues and estimates for the phase. The market background is discussed in the report which sheds a light on the key drivers, threats, patterns and opportunities in the demand for bioinformatics market. A global overview has been presented for bioinformatics products, supply chain analysis and hazard analysis, which is expected to help readers identify the key factors that support the growth of the demand for bioinformatics market. The report discusses the regulatory scenario affecting approvals for the products, across leading regions. It also provides information on the demand of the bioinformatics market adopted in leading countries. It includes a specific list of retailers and manufacturers dealing in bioinformatics market. Readers will also be able to find regional developments and regulations that impact market growth. Significant growth prospects are given for countries which also include key regional developments and factors that influence the growth of the demand for bioinformatics market. The report studies business patterns of top companys like- fujifilm holdings corporation, analogic corporation, siemens healthcare, esaote s.p.a, toshiba medical systems corporation, ge healthcare, philips healthcare, hitachi medical corporation, and mindray medical international ltd

Get TOC For The Overview Of The Premium Report:https://www.quincemarketinsights.com/request-toc-60484?utm_source=SSK&utm_medium=3WN&utm_campaign=SSK

Bioinformatics market growth is expected to gain high momentum during the forecast period due to increasing demand for imaging devices for diagnostics applications. An ceiling-mounted surgical lights is a medical imaging device, which uses high-frequency waves to visualize the internal organs of the body such as blood vessels, kidney, liver, human foetus, heart, etc. This market is gaining momentum, owing to the increase in the number of hospitals and adoption of technologically advanced devices, which can serve the purpose for both diagnostics and therapeutics. Moreover, the cumulative prevalence of cancer is driving the demand for early detections and minimization of expenses. According to the Cancer Research Institute (CRI), there were approximately 17 million new cases of cancer globally, as of 2017, which is also fuelling the demand for ultrasound devices.

Segment Analysis

The bed head multifunctional belt market has been segmented by type (platforms, tools, services), by applications (preventive medicine, molecular medicine, gene therapy drug development). Based on portability, the market can be divided into trolley/cart and compact/handheld. Based on application, the market has been divided into radiology, gynaecology, urology, cardiology, orthopaedic/musculoskeletal, and others. Owing to the growing incidences of stem cell-based injuries and the demand for high-quality diagnostic procedures, the radiology segment is expected to lead. The market has been studied for North America, Western Europe, Eastern Europe, Asia Pacific, and Rest of the World.

Key Factors Impacting Market Growth:

Regional Outlook:

North America, Western Europe, and Asia Pacific by region are estimated to dominate the ultrasound market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favourable for the growth of the healthcare infrastructure in these regions. North America and Western Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for ultrasound market during the forecast period.

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for ultrasound market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for ultrasound market in the region. Other regions including Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for ultrasound during the forecast period.

Speak To Analyst before Buying This: https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-60484?utm_source=SSK&utm_medium=3WN&utm_campaign=SSK

Market Segmentation:

By Type Platforms Tools Services

By Applications Preventive Medicine Molecular Medicine Gene Therapy Drug Development

By Region:

Major Companies:Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc., CLC bio A/S, Agilent Technologies Inc., GenoLogics Life Sciences Software, Inc., Life Technologies Corporation, Illumina, Inc.

Reasons to Buy This Report:

Customization:

We provide customization of the study to meet specific requirements:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: US +1 208 405 2835 / UK +44 121 364 6144 / APAC +91 706 672 4848

Email:[emailprotected]

Web: http://www.quincemarketinsights.com

Read more here:

Global Bioinformatics Market To See Booming Worldwide | Top Key Players- Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc. - 3rd Watch News

Cytokine-induced molecular responses in airway smooth muscle cells inform genome-wide association studies of asthma. – Physician’s Weekly

A challenge in the post-GWAS era is to assign function to disease-associated variants. However, available resources do not include all tissues or environmental exposures that are relevant to all diseases. For example, exaggerated bronchoconstriction of airway smooth muscle cells (ASMCs) defines airway hyperresponsiveness (AHR), a cardinal feature of asthma. However, the contribution of ASMC to genetic and genomic studies has largely been overlooked. Our study aimed to address the gap in data availability from a critical tissue in genomic studies of asthma.We developed a cell model of AHR to discover variants associated with transcriptional, epigenetic, and cellular responses to two AHR promoting cytokines, IL-13 and IL-17A, and performed a GWAS of bronchial responsiveness (BRI) in humans.Our study revealed significant response differences between ASMCs from asthma cases and controls, including genes implicated in asthma susceptibility. We defined molecular quantitative trait loci (QTLs) for expression (eQTLs) and methylation (meQTLs), and cellular QTLs for contractility (coQTLs) and performed a GWAS of BRI in human subjects. Variants in asthma GWAS were significantly enriched for ASM QTLs and BRI-associated SNPs, and near genes enriched for ASM function, many with small P values that did not reach stringent thresholds of significance in GWAS.Our study identified significant differences between ASMCs from asthma cases and controls, potentially reflecting trained tolerance in these cells, as well as a set of variants, overlooked in previous GWAS, which reflect the AHR component of asthma.

PubMed

See more here:

Cytokine-induced molecular responses in airway smooth muscle cells inform genome-wide association studies of asthma. - Physician's Weekly

Coronavirus morning update: Public schools to shut, and Covid corruption warning – Health24

WHAT'S HAPPENING IN SA

Cases update:

The latest number of confirmed cases is 408 052.

According to the latest update, 6 093 of deaths have been recorded in the country.

There have been 236 260 recoveries.

So far, just over 2.6 million tests have been conducted, with 46 632 new tests.

READ MORE | All the confirmed cases of coronavirus in SA

Latest news:

A week after teachers' unions called for schools to close amid the upcoming peak in Covid-19 infections in South Africa, Cabinet has decided to shut all public schools for four weeks - but there are exceptions.

President Cyril Ramaphosa announced on Thursday, while addressing the nation, that public schools would close from 27 July to 24 August.

Grade 12s will, however, only take a week's break and return on 3 August.

Grades 7s will get a two-week break, returning on 10 August.

"Specific arrangements will be made for different categories of special schools. As a result of the disruptions caused by the pandemic, the current academic year will be extended beyond the end of 2020.

"The minister of basic education will provide details on the management of the remainder of the school year," said Ramaphosa.

Ramaphosa said the decision was taken following engagement with the Department of Basic Education and more than 60 organisations representing parents, school governing bodies, principals, educators, independent schools and civil society organisations.

READ |Ramaphosa declares schools will shut for 4 weeks - but Grade 12s get 1 week's break

The coronavirus has infected around 13 000 health workers and killed more than 100 of them, the health department said on Thursday, as the virus takes its toll on frontline caregivers.

The country has the highest number of infections on the continent, with 394 948 recorded cases and 5 940 deaths as of Wednesday.

It is also the world's fifth worst-affected country in terms of diagnosed infections.

Health Minister Zweli Mkhize's spokesperson, Popo Maja, told AFP that 13 174 health workers had become infected as of Tuesday, including 103 deaths and 6 394 people declared recovered.

The country's statistics were unveiled as the World Health Organization (WHO) reported more than 10 000 health workers in 40 countries had been sickened by the virus.

"The growth we are seeing in Covid-19 cases in Africa is placing an ever-greater strain on health services across the continent," said Matshidiso Moeti, WHO regional director for Africa, at a news conference on Thursday.

"This has very real consequences for the individuals who work in them, and there is no more sobering example of this than the rising number of health worker infections," she said.

READ MORE |More than 13 000 health workers contracted coronavirus - health dept

President Cyril Ramaphosa on Thursday vowed to crack down on corruption or mismanagement relating to Covid-19 relief funds, saying the consequences would be "very, very severe" for those found guilty.

In an address to the nation in the evening, the president said the government had established a "coordinating centre" to strengthen efforts between law enforcement agencies and investigate allegations of corruption relating to social relief grants, procurement of personal protective equipment, and distribution of food parcels.

A total of 36 cases are already at an advanced stage of investigation, the president said, without going into specifics.

The coordinating hub, which is based at the Financial Intelligence Centre, brings together nine state institutions including the FIC, the Independent Police Investigative Directorate, the National Prosecuting Authority, the Hawks, the South African Revenue Service, the State Security Agency and the Special Investigations Unit.

READ MORE |Ramaphosa vows 'very, very severe' consequences for theft of Covid-19 relief funds

Health Minister Zweli Mkhize has announced urgent support for the Eastern Cape's health authorities in the wake of record deaths in the past few days - more than 400 reported in Wednesday's update.

At a press conference in Port Elizabeth on Thursday, Mkhize announced a high-powered "project management team" has been appointed to "to help the health service to cope better".

This, after project management had been identified as a "weakness" in the province. The skilled team would assist health authorities with "quick decision-making" and "agility", in particular.

Second, the Eastern Cape is being assisted with infrastructure and equipment. Overall, all available hospital beds are not yet filled - but the province is witnessing shortages in specific.

"Some of the smaller hospitals are taking strain," Mkhize said on eNCA. Efforts would now be made to increase beds "in areas of need... because of the vastness of the province".

READ MORE |Mkhize unlocks urgent help for Eastern Cape as Covid-19 deaths soar

Tracing and retesting of 111 people, whose Covid-19 samples were lost when criminals pounced on a courier truck during a heist in Port Elizabeth on Monday, is underway.

National Health Laboratory Service spokesperson Mzimasi Gcukumana said: "The NHLS have allocated healthcare workers to contact the patients and make arrangements to collect new samples."

The bio-hazard samples went missing on Monday when two workers, from a courier company hired by the NHLS to collect samples from local clinics, were ambushed by two gunmen.

The incident happened at 15:30 in Motherwell's NU 11 section. The truck was found abandoned 500m away with the samples missing. The courier drivers were also robbed at gunpoint of their cellphones.

The police are investigating a case of hijacking. The suspects remain at large, confirmed police spokesperson Colonel Priscila Naidu.

READ MORE |Covid-19: More than 100 people must now be retested after samples lost in PE truck hijacking

WHAT'S HAPPENING IN THE REST OF THE WORLD

Cases update:

For the latest global data, follow this interactive map from Johns Hopkins University & Medicine.

Late on Thursday night, positive cases worldwide were over 15.3 million, while deaths were more than 625 000.

The United States had the most cases in the world - just over 4 million, as well as the most deaths - close to 144 000.

READ MORE |All the confirmed cases worldwide

Latest news:

Australia reported its highest daily number of coronavirus-related deaths in three months on Thursday as new infections continued to climb in its second most populous state.

Victoria state said it had confirmed another 403 infections, while five people had died from the virus in the last 24 hours.

The fatalities, including a man in his 50s, mark the country's biggest one-day rise in Covid-19 deaths since late April.

"This demonstrates the growing toll this terrible virus is taking on our community," Health Minister Jenny Mikakos told reporters in the state capital, Melbourne.

With authorities unable to bring new infections below triple digits, residents in Melbourne and most of the state are now required to wear masks outside of their homes.

READ MORE |Australia reports highest coronavirus deaths in 3 months, infections climb

The Republic of Zimbabwe enforced one of the strictest nationwide lockdowns in Africa on Wednesday after the number of active coronavirus cases surpassed the number of recoveries in the country.

However, activists and commentators believe the new lockdown measures were introduced in light of the arrest of award-winning Zimbabwean journalist Hopewell Chin'ono and a planned nationwide protest on 31 July.

Zimbabwe, one of South Africa's closest neighbours and a major export partner, confirmed 1 820 Covid-19 cases, including 488 recoveries and 26 deaths.

This is up from 605 cases, 166 recoveries and seven deaths at the beginning of July.

News24 took a look at why Zimbabwe enforced such a strict national lockdown, and why commentators are questioning the government's motives.

EXPLAINER | What's happening in Zimbabwe regarding Covid-19?

This year's haj will be a time of sadness for many Muslims around the world prevented from travelling to Saudi Arabia, but a decision to honour local health and security staff in the front line of the fight against the coronavirus has won praise.

For the first time in the modern era, amidst efforts to curb Covid-19, Muslims from abroad will be unable to attend the pilgrimage.

This year's event has been limited to about 1 000 pilgrims from within Saudi Arabia, 70% of whom will be foreign residents of the kingdom.

The remaining 30% will be drawn from Saudi healthcare workers and security personnel who have recovered from the coronavirus, as a gesture of thanks for their sacrifice.

"Haj this year is for the heroes who saved the country and saved our people, they deserve it ... I personally would have loved to go but there are priorities," said Saudi citizen Nour al Ghamdi.

READ MORE |Pandemic hit to haj saddens would-be pilgrims

LATEST RESEARCH & HEALTH NEWS

As South Africa is experiencing a surge in coronavirus cases, overtaking European hotspots like Italy, Spain and the UK in total case numbers, our cumulative case-fatality rate (CFR) appears to be a lot lower.

As of 22 July, South Africa has nearly 395 000 confirmed cases, with 5 940 deaths. The UK has had more 45 586 deaths (nearly 297 000 cases) Spain more than 28 426 (more than 267 000 cases) and Italy more than 35 082 (more than 245 000 cases), despite lower case numbers.

While the stats are impacted by targeted testing strategies with an assumed high rate of underdetection, experts have given Health24 a few possible reasons why our mortality rate is lower.

An important concept to grasp is to understand the calculation of the CFR, says Professor Taryn Young, head of Stellenbosch University's Epidemiology and Biostatistics.

This looks at the confirmed number of deaths compared with the confirmed number of cases by dividing the number of deaths by the number of confirmed cases.

"How countries define and report Covid-19-related deaths is important," says Young. "There is the definition on the one hand, and on the other how it gets reported. For example, reporting based on death certificate will take longer and may not reflect in the data on the day the person died."

READ MORE |Covid-19: More cases than UK, Spain, Italy - but SA has lower mortality rate - we asked experts why

Oxford Universitys Covid-19 vaccine candidate, AZD-1222, proved to be safe and effective with few side effects, preliminary trial results showed on Monday. According to pharmaceutical company AstraZeneca, they have finalised a license agreement with Oxford University for the vaccine candidate.

Earlier this week, the BBC initially reported that the UK government has already ordered 100 million doses of the Oxford vaccine, and later added that the government signed deals for an additional 90 million doses of the other promising BioNtech/Pfizer and Valneva vaccines. (These two vaccines are being researched by an alliance between the pharmaceutical companies BioNtech and Pfizer, as well as the firm Valneva.)

AstraZeneca, however, doesnt have any direct involvement with South Africas vaccine trial as the agreement to do the trial here preceded Oxfords agreement with AstraZeneca for further clinical development and manufacturing of the vaccine, said Shabir Madhi, Professor of Vaccinology at the University of the Witwatersrand (Wits) in Johannesburg, during an ECN (Economist Corporate Network) Africa webinar today. Madhi is leading the SA trial.

South Africas Covid-19 vaccine trial is being funded by the South African Medical Research Council (SAMRC) and the Bill and Melinda Gates Foundation.

At the moment, there is no agreement with AstraZeneca to prioritise access to the vaccine for South Africa, should it prove successful. But this wouldnt be unique to South Africa, said Madhi.

READ MORE |Covid-19 vaccine trial in SA: Will we have access to treatment if it is a success, and approved?

Earlier this week, Health24 reported on the latest development in the Oxford coronavirus vaccine trial that began in April. Preliminary results, published in The Lancet, showed that the vaccine, named AZD-1222, triggered a positive immune response in participants and indicated no early safety concerns.

Although the results so far are promising, we still have a long way to go. Health24 spoke to Honorary Professor Robert Wilkinson from the Institute of Infectious Disease and Molecular Medicine (IDM) at the University of Cape Town (UCT), and Director of The Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa); and Professor Thomas Scriba, Deputy Director of Immunology and Laboratory Director at UCT, about the steps ahead.

The recently published results are a positive breakthrough, no doubt, but is it too early to get excited about the possibility of a vaccine? Well, it depends on how you look at it.

The fact that there were no serious adverse events recorded in this trial is definitely a positive result and an exciting one," said Scriba, adding: "Of course, we shouldnt get ahead of ourselves and think that this [vaccine] is ready to be rolled out. Thats not the case. But its an important step forward.

Its also critical that the testing is done in other countries with diverse population groups, so that the results can accurately represent the population group, and so that we know its safe to be used in these groups, explained Scriba. South Africa, Brazil and the US are also currently running trials, with results in SA expected as early as November, Health24 recently reported.

READ MORE |Oxford vaccine trial step in right direction, but challenges still ahead

HEALTH TIPS(as recommended by the NICD and WHO)

Maintain physical distancing stay at least one metre away from somebody who is coughing or sneezing

Practise frequent hand-washing, especially after direct contact with ill people or their environment

Avoid touching your eyes, nose and mouth, as your hands touch many surfaces and could potentially transfer the virus

Practise respiratory hygiene cover your mouth with your bent elbow or tissue when you cough or sneeze. Remember to dispose the tissue immediately after use.

Image credit: Getty Images

More here:

Coronavirus morning update: Public schools to shut, and Covid corruption warning - Health24

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. – GlobeNewswire

Daniel M. Skovronsky, M.D., Ph.D. Elected to Myriads Board of Directors. Walter (Wally) Gilbert, Ph.D., announces upcoming retirement from the Board of Directors

SALT LAKE CITY, July 22, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced the election of Daniel M. Skovronsky, M.D., Ph.D., age 47, to its Board of Directors, effective immediately, expanding the Board to ten members. Additionally, Dr. Skovronsky was appointed to the Research and Product Innovation Committee of Myriads Board.

Dr. Skovronsky serves as Chief Science Officer and President of Lilly Research Laboratories at Eli Lilly and Company. He previously served as the Founder and Chief Executive Officer of Avid Radiopharmaceuticals, Inc. which used non-invasive imaging to detect the early changes in the brain related to Alzheimers disease. Dr. Skovronsky received his M.D., Ph.D. from University of Pennsylvania where he also completed sub-specialty training in neuropathology.

We are honored to welcome Dr. Skovronsky to the Myriad Board, said Louise Phanstiel, Chair of the Board of Myriad. Dan brings a wealth of experience and expertise in research and development in multiple areas related to our diagnostic product development, including oncology, neuroscience, and anti-inflammatory diseases. He will be instrumental in providing product development strategic insights in executing our global strategy for molecular diagnostics and precision medicine.

The Company also announced today that Director, Vice Chair of the Board, Walter (Wally) Gilbert, Ph.D., will retire from the board at the Companys Annual Meeting of Stockholders in December 2020. Dr. Gilbert, co-founder of Myriad, has been on the board since March 1992. Dr. Gilbert received a Nobel Prize in Chemistry in 1980 for his development of a rapid DNA sequencing technology. I am proud that Myriad has grown to realize its founders dream of using tests based on genetic information to identify a patients predisposition to disease, said Dr. Gilbert. Myriad is dedicated to providing critical, life-changing information to people to help define their individual medical needs. I have enjoyed helping the company grow over the years. I am confident that Myriads important work for patients will continue.

In commenting on Dr. Gilberts pending retirement, Louise Phanstiel said, The Board owes a tremendous debt of gratitude to Wally for all of his countless contributions to the company and to the board over the years. His relentless focus on the pursuit of scientific excellence and compassion for our patients as well as our Myriad team are qualities we all aspire to emulate. The board, the company and I will greatly miss his wisdom, counsel and passion. We wish Wally all the best.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Dr. Skovronsky providing product development strategic insights in executing the Companys global strategy for molecular diagnostics and precision medicine; Dr. Gilbert retiring from the Companys board at the Companys Annual Meeting of Stockholders in December 2020; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Media Contact: Jared Maxwell (801) 505-5027 jmaxwell@myriad.com

Investor Contact: Scott Gleason(801) 584-1143sgleason@myriad.com

See more here:

Myriad Genetics Expands Board of Directors with New Member and Announces Upcoming Retirement of Walter (Wally) Gilbert, Ph.D. - GlobeNewswire

Encoded Therapeutics Raises $135M in Series D Financing – FinSMEs

Encoded Therapeutics, Inc., a South Francisco, Calif.-based precision gene therapy company, raised $135m in Series D financing.

The round was led by GV (formerly Google Ventures) with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 21, and additional unnamed investors. In conjunction with the funding, David Schenkein, M.D., general partner and co-leader of GVs life sciences team, will join the Encoded Board of Directors as an observer.

Led by co-founder and chief executive officer, Kartik Ramamoorthi, Ph.D., Encoded is a biotechnology company developing precision gene therapies for a broad range of severe genetic disorders. It is advancing its lead asset, ETX101, for the treatment of SCN1A+ Dravet Syndrome by leveraging a discovery engine that combines biological and computational approaches to identify and screen human DNA sequences known as regulatory elements at a high throughput scale.

The company intends to use the funds to advance its lead asset, ETX101, which was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA) for the treatment of SCN1A+ Dravet Syndrome.

Proceeds from the Series D will be used to conduct clinical trial activities including a natural history study to better understand the progression of SCN1A+ Dravet Syndrome as well as first-in-human trials for ETX101. Additionally, the funds will support progression of the companys pipeline of gene therapies being evaluated for additional pediatric CNS disorders.

FinSMEs

23/07/2020

Original post:

Encoded Therapeutics Raises $135M in Series D Financing - FinSMEs

MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy – Xconomy

XconomyNew York

A gene therapy being jointly developed by MeiraGTx and Johnson & Johnson to treat an inherited disease of the retina that leads to blindness improved patients vision after six months, data that the companies say is enough to move the potentially long-lasting treatment into pivotal testing.

The condition, called X-linked retinitis pigmentosa, is part of a group of vision disorders that collectively represent the most common cause of inherited blindness. X-linked RP, or XLRP, the most aggressive form of retinitis pigmentosa, significantly impairs patients quality of life as the disease progresses. No treatments currently exist.

The MeiraGTx (NASDAQ: MGTX) treatment is designed for patients whose XLRP is caused by mutations in the gene RPGR, which cause about 70 percent of XLRP cases and up to 20 percent of all retinitis pigmentosa cases. MeiraGTxs gene therapy is delivered via subretinal injection.

A Phase 1/2 trial, underway at five sites in the US and UK, tested three doses in 10 male patients age 5 and older for safety and tolerability. In each patient one eyethe one with worse sightwas treated; the other eye was used as a control.

Secondary goals included retinal sensitivity, which after six months had improved or stabilized in five of the seven in the low and intermediate dose groups, according to the interim data. No improvement was observed in the high dose cohort; it wont be tested in future trials. Signs of improvement were detected at the first assessment, which took place at three months, improvements that were generally sustained or increased at the next evaluation.

Most of the adverse events recorded were associated with the surgical procedure used to deliver the treatment, according to MeiraGTx; two of three patients in the high-dose cohort experienced inflammation, which was controlled with steroids.

The data were presented at the annual meeting of the American Society of Retina Specialists, which was held virtually. The interim results support advancing the treatment into a Phase 3 triala first for MeriaGTx, which was founded about five years ago, president and CEO Zandy Forbes said on a conference call Friday.

Johnson & Johnson (NYSE: [[ticker:J&J]]) made a bet on the gene therapy pipeline being developed by MeiraGTx in January 2019, when the companies inked a $100 million deal giving the pharma giant rights to the biotechs investigational XLRP treatment, plus others in its pipeline, as part of a pact to jointly develop and commercialize gene therapies to treat inherited retinal diseases. Under the terms of that deal, MeiraGTx is eligible for up to $340 million more based on the programs progression.

Including the XLRP program, MeiraGTxwhich has offices in London and New Yorkis advancing six clinical-stage programs, half of them under its collaboration with J&J. The companys initial focus is on diseases that impact the eye, central nervous system, and salivary glands.

The first-ever gene therapy approved in the US, Spark Therapeutics voretigene neparvovec (Luxturna), was for patients with an inherited retinal disease that can lead to blindness. Its 2018 approval led to the companys acquisition the following year by Roche, which splashed out $4.8 billion for the Philadelphia-based firm. Spark priced its treatment at $850,000.

Image: iStock/monkeybusinessimages

Sarah de Crescenzo is an Xconomy editor based in San Diego. You can reach her at sdecrescenzo@xconomy.com.

More here:

MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy - Xconomy

Investment Analysis On: Gene Therapy MARKET ? GROWING TRADE AMONG EMERGING ECONOMIES OPENING NEW OPPORTUNITIES (2020-2026) – 3rd Watch News

Global Gene Therapy Market Research Report 2020: COVID-19 Outbreak Impact Analysis

The Gene Therapy market research report drafted by Brand Essence Market Research elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the research study covers every pivotal aspect of this business sphere that influences the existing trends, profitability position, market share, market size, regional valuation, and business expansion plans of key players in the Gene Therapy market.

Download Premium Sample of the Report: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=165836&RequestType=Sample

Latest research report on Gene Therapy Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrates its growth trends and competitive landscape as well as the key players in the business.

Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the markets growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

This report focuses on the global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China.

The key players covered in this study RetroSense Therapeutics REGENXBIO AGTC

Market segment by Type, the product can be split into Subretinal Intravitreal Unspecified

Market segment by Application, split into Monotherapy Combination Therapy

In this study, the years considered to estimate the market size of Gene Therapy for Age-related Macular Degeneration are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

Market segment by Regions/Countries, this report covers United States Europe China Japan Southeast Asia India Central & South America

The study objectives of this report are: To analyze global Gene Therapy for Age-related Macular Degeneration status, future forecast, growth opportunity, key market and key players. To present the Gene Therapy for Age-related Macular Degeneration development in United States, Europe and China. To strategically profile the key players and comprehensively analyze their development plan and strategies. To define, describe and forecast the market by product type, market and key regions.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

>>>>Get Full Customize report@ https://brandessenceresearch.biz/Request/Sample?ResearchPostId=165836&RequestType=Customization

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

The Essential Content Covered in the GlobalGene Therapy Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

The report provides a 6-year forecast (2020-2026) assessed based on how the Gene Therapy market is predicted to grow in major regions like USA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Strategic Points Covered in TOC:

Chapter 1:Introduction, market driving force product scope, market risk, market overview, and market opportunities of the global Gene Therapy market.

Chapter 2:Evaluating the leading manufacturers of the global Gene Therapy market which consists of its revenue, sales, and price of the products.

Chapter 3: the competitive nature among key manufacturers, with market share, revenue, and sales.

Chapter 4:Presenting global Gene Therapy market by regions, market share and revenue and sales for the projected period.

Chapters 5, 6, 7, 8 and 9:To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Read More: https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Top-Growth-On-Gene-Therapy-for-Age-related-Macular-Degeneration-Market-Size-and-Share/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at[emailprotected]

Top Trending Reports:

https://www.marketwatch.com/press-release/silver-dressings-bandages-market-size-industry-analysis-report-regional-outlook-application-development-potential-price-trends-competitive-market-share-forecast-20202025-2020-07-22?tesla=y

https://sites.google.com/view/themarkets/biotechnology/bioinformatics-service-market-expected-to-reach-4-96-billion-by-2026

https://sites.google.com/view/themarkets/heavy-industry/garden-furniture-market-expected-to-reach-usd-20032-93-million-by-2025

https://www.marketwatch.com/press-release/uk-anhydrous-milk-fat-market-size-share-growth-opportunities-and-market-forecast-2020-to-2025-2020-07-22?tesla=y

https://teletype.in/@nikhils/MjSVWuqus

Read the rest here:

Investment Analysis On: Gene Therapy MARKET ? GROWING TRADE AMONG EMERGING ECONOMIES OPENING NEW OPPORTUNITIES (2020-2026) - 3rd Watch News

Gracell Expands Executive Team by Appointment of CMO Dr. Martina Sersch and CFO Dr. Kevin Xie – PRNewswire

SHANGHAI and SUZHOU, China, July 23, 2020 /PRNewswire/ --Internationally renowned clinical-stage immune cell and gene therapy company, Gracell Biotechnologies Co., Ltd. ("Gracell" or "the Company") has announced two appointments to the executive suite. Chief Medical Officer Dr. Martina Sersch, MD and Chief Financial Officer Kevin Xie, PhD, MBA both bringing extensive knowledge and leadership experience to Gracell. Along with CEO Dr. William Cao, Dr. Sersch and Dr. Xie joined Gracell in their respective functions to support the company's mission of providing novel cellular therapies for unmet medical needs.

"We are delighted that Dr. Martina Sersch and Dr. Kevin Xie joined Gracell," said Dr. William Cao, CEO of Gracell. "Gracell has achieved many significant milestones since its founding, and with the recent addition of Dr. Sersch and Dr. Xie to our executive leadership team, Gracell will be advancing faster to achieve future breakthroughs."

CMO Dr. Martina Sersch brings over 25 years of experience in academia and industry, as well as an exceptional wealth of talent and knowledge to the Company. Prior to Gracell, Martina was CMO of a Nasdaq-listed CAR-T and gene therapy company, leading the development of novel cell and gene therapies for rare diseases and oncology indications. In addition, she previously served roles of increasing responsibility in Oncology Development as well as Medical Affairs at Pfizer, Genentech/Roche and Amgen, including leading the development of CAR-T therapies, gene therapies and immuno-oncology products in hematology and solids tumors. She oversaw the development and successful filing activities of multiple early- and late-stage products regionally and globally including US, Europe and Asia. Dr. Sersch received her MD and doctorate degree from the University of Heidelberg in Germany.

"Gracell has made significant achievements in multiple projects developing FasTCAR and TruUCARTM platform which were recently presented at major conferences in the treatment for hematological malignancies and solid tumors," said Dr. Martina Sersch, "As CMO, I am excited to continue to lead an incredible team with very talented researchers in our quest in developing innovative medicines for people with high unmet medical need.

CFO Dr. Kevin Xie came to Gracell with extensive healthcare finance and investment experience in leadership positions. Prior to Gracell, Dr. Xie was most recently the President of Fosun Healthcare Holdings and Chief Representative of Fosun in New York. Before Fosun, Dr. Xie served in senior positions at multiple global healthcare investment funds for over ten years, including as the co-founder of Locust Walk Capital, healthcare sector head at Scopia Capital and a managing director at Great Point Partners. Dr. Xie holds an MBA from The Wharton School and a PhD in Chemistry from the City University of New York.

"After twenty years of investing and advising healthcare companies, I am excited to join Gracell to lead the Company's finance and business development activities, and together with R&D team to build Gracell to be a leader in cell and gene therapy industry," said Dr. Kevin Xie, "I can see Gracell is poised to translate its industry-leading research programs into the transformative treatments, which could change millions of patients' lives worldwide. By joining and leading Gracell's finance organization at this exciting stage of its development, I wish to help deliver that promise as the company progresses to the next phase of strategy."

About Gracell

Gracell Biotechnologies Co., Ltd. ("Gracell") is a clinical-stage biotechnology company, committed to developing highly efficacious and affordable cell and gene therapies for the treatment of cancer. Gracell is dedicated to resolving the remaining challenges in CAR-T, such as high production costs, lengthy manufacturing process, lack of off-the-shelf products, and inefficacy against solid tumors. Led by a group of world-class scientists, Gracell is advancing FasTCAR (overnight production and younger cell phenotype), TruUCAR (off-the-shelf), DualCAR and EnhancedCAR T cell therapies for leukemia, lymphoma, myeloma, and solid tumors.

CONTACT:

Kevin XIECFO[emailprotected]

Linc HEBusiness Development and Public Relations[emailprotected] +86-21-6403-1375

SOURCE Gracell

http://www.gracellbio.com

Read more here:

Gracell Expands Executive Team by Appointment of CMO Dr. Martina Sersch and CFO Dr. Kevin Xie - PRNewswire

GenScript launches CDMO segment "GenScript ProBio" at inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum…

At the Forum, GenScriptannounced the integration and upgrading of the original CDMO platform and the release of its latest brand GenScript ProBio. The new brand is dedicated to proactively providing end-to-end service from discovery to commercialization withprofessional solutions and efficientprocesses to accelerate drug development for customers.

For the past 16 years, since 2004, GenScript has gradually expanded its reach in the antibody drug discovery segment and established its capabilities in process development, helping many customers with their IND approvals during the period. In 2019, GenScript opened the Biologics Development Business Unit (BDBU), the predecessor of GenScript ProBio, and invited Dr. Brian Min, SeniorVicePresidentatSamsungBioepis, to join as CEO and form a management team with exceptional international perspectives. The core members of the team each have more than 15 years working experience at recognized international firms across the sector, including Roche, Pfizer, Henlius and Innovent, among others.

GenScript ProBio has established long-term partnerships with many industry leaders worldwide with the specific aim of advancing the development of the biopharmaceutical industry.

"The GenScript CDMO platform has established strong antibody capabilities within just 18 months since launch and has accumulated considerable experience in cell and gene therapy," said Dr. Brian Min at the launch of the brand."GenScript ProBio's one-stopantibody drug development solutions will proactively provide clients with end to end service from target to commercialization. Looking beyond China and the Asia Pacific region, many large multinational companies in the United States and Europe have also established productive partnerships with us. Operating under the principle of'Innovation through Collaboration', we fully expect to drive the development and progress of the whole industry together with our customers."

GenScript ProBio has been committed to accelerating the development of the cell therapy sector and helping firms within the sector accelerate the commercialization of cell therapy products. With the advent of the era of cell and gene therapy, GenScript ProBio plans to continue providing process optimization and production in line with international quality standards through a sound global supply chain network, empowering more partners worldwide to benefit patients anywhere at an early date.

GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO arm of the world's leading biotech company GenScript, providing end-to-end services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes to accelerate drug development for customers.

In line with the mission of "Innovation through Collaboration", GenScript ProBio is committed to helping customers shorten the time-to-market for biological drugs from discovery to commercialization, significantly lowering R&D costs and building a healthier future.

https://www.genscriptprobio.com/

SOURCE GenScript ProBio

https://www.genscriptprobio.com/

Link:

GenScript launches CDMO segment "GenScript ProBio" at inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum...

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed…

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that Dr. George K. Gittes, MD of the University of Pittsburgh, the lead researcher that developed the Companys potentially curative diabetes gene therapy, was awarded a grant of $2.59 million from the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases. The grant will assist Dr. Gittess development for his research project titled, Alpha Cell Conversion to Beta Cells in Non-human Primates and will build upon his accumulating groundbreaking gene therapy work toward finding a cure for diabetes. In this project, Dr. Gittes research team will conduct important proof-of-principle studies in non-human primates as the last steps in preparation for human gene therapy clinical trials. This technology is the subject of an exclusive license agreement entered into between Genprex and the University of Pittsburgh in February of 2020.

We are excited to receive this funding to support our research in diabetic primates as we move toward human clinical trials, said Dr. George Gittes, Co-Scientific Director and Professor of Surgery at the UPMC (University of Pittsburgh Medical Center) Childrens Hospital of Pittsburgh and the lead researcher behind the diabetes gene therapy. We saw encouraging data in our preclinical mice studies, where the gene therapy reprogrammed pancreatic cells to restore normal blood glucose levels in diabetic mice for approximately four months, which could translate to decades in humans. More recently, preliminary results in non-human primates (monkeys) has also been very promising.

Dr. Gittes gene therapy for diabetes, which Genprex refers to as GPX-002, uses a novel infusion process comprised of an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes to the pancreas. The genes express proteins that transform alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the bodys immune system.

Diabetes affects approximately 10 percent of the U.S. population, or more than 34 million people. The diabetes gene therapy could not only become a new treatment option for millions of diabetes patients who need insulin replacement therapy, but it holds the potential to provide long-term effectiveness, or may even be a cure, for diabetic patients.

Dr. Gittes is the inventor of the gene therapy for diabetes, and he is eligible to receive royalties on this technology in the future.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

The project described in this press release is being supported by the National Institute of Diabetes and Digestive And Kidney Diseases of the National Institutes of Health under Award Number R01DK120377. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of GPX-001, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including GPX-002, our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our product candidates; the timing and success at all of obtaining FDA approval of GPX-001 and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Link:

National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed...